Free Trial
→ The SpaceX supplier that shipped 5 billion chips to Starlink (From Weiss Ratings) (Ad)tc pixel Free MBIO Stock Alerts

Mustang Bio (MBIO) Competitors

Mustang Bio logo
$0.63 0.00 (0.00%)
As of 05/22/2026 04:00 PM Eastern
Compare

MBIO vs. ANEB, XCUR, LPCN, KTTA, and QNCX

Should you buy Mustang Bio stock or one of its competitors? MarketBeat compares Mustang Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Mustang Bio include Anebulo Pharmaceuticals (ANEB), Exicure (XCUR), Lipocine (LPCN), Pasithea Therapeutics (KTTA), and Quince Therapeutics (QNCX). These companies are all part of the "pharmaceutical products" industry.

How does Mustang Bio compare to Anebulo Pharmaceuticals?

Mustang Bio (NASDAQ:MBIO) and Anebulo Pharmaceuticals (NASDAQ:ANEB) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, profitability, risk, analyst recommendations, valuation, earnings and institutional ownership.

Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$1.92M-$0.48N/A
Anebulo PharmaceuticalsN/AN/A-$8.48M-$0.19N/A

In the previous week, Anebulo Pharmaceuticals had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Anebulo Pharmaceuticals and 0 mentions for Mustang Bio. Mustang Bio's average media sentiment score of 0.00 equaled Anebulo Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Mustang Bio Neutral
Anebulo Pharmaceuticals Neutral

Mustang Bio's return on equity of -35.38% beat Anebulo Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang BioN/A -35.38% -16.36%
Anebulo Pharmaceuticals N/A -74.57%-68.96%

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 28.4% of Anebulo Pharmaceuticals shares are held by institutional investors. 4.0% of Mustang Bio shares are held by company insiders. Comparatively, 80.6% of Anebulo Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Mustang Bio has a beta of 2.11, suggesting that its share price is 111% more volatile than the broader market. Comparatively, Anebulo Pharmaceuticals has a beta of -1.93, suggesting that its share price is 293% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Anebulo Pharmaceuticals
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.50

Summary

Mustang Bio and Anebulo Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does Mustang Bio compare to Exicure?

Mustang Bio (NASDAQ:MBIO) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, risk, valuation, dividends, analyst recommendations, earnings and institutional ownership.

In the previous week, Mustang Bio's average media sentiment score of 0.00 equaled Exicure'saverage media sentiment score.

Company Overall Sentiment
Mustang Bio Neutral
Exicure Neutral

Mustang Bio's return on equity of -35.38% beat Exicure's return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang BioN/A -35.38% -16.36%
Exicure N/A -138.71%-62.76%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Exicure
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Mustang Bio has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Exicure has a beta of 3.62, suggesting that its stock price is 262% more volatile than the broader market.

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 4.0% of Mustang Bio shares are held by insiders. Comparatively, 52.8% of Exicure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Mustang Bio has higher earnings, but lower revenue than Exicure. Exicure is trading at a lower price-to-earnings ratio than Mustang Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$1.92M-$0.48N/A
Exicure$500K35.80-$4.95M-$0.77N/A

Summary

Mustang Bio beats Exicure on 5 of the 9 factors compared between the two stocks.

How does Mustang Bio compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Lipocine had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Lipocine and 0 mentions for Mustang Bio. Lipocine's average media sentiment score of 0.00 equaled Mustang Bio'saverage media sentiment score.

Company Overall Sentiment
Lipocine Neutral
Mustang Bio Neutral

Lipocine has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.11, meaning that its stock price is 111% more volatile than the broader market.

Lipocine currently has a consensus price target of $15.00, indicating a potential upside of 563.72%. Given Lipocine's stronger consensus rating and higher possible upside, equities research analysts plainly believe Lipocine is more favorable than Mustang Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Lipocine
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Mustang Bio has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Mustang Bio's return on equity of -35.38% beat Lipocine's return on equity.

Company Net Margins Return on Equity Return on Assets
Lipocine-571.18% -66.70% -59.39%
Mustang Bio N/A -35.38%-16.36%

Mustang Bio has lower revenue, but higher earnings than Lipocine. Mustang Bio is trading at a lower price-to-earnings ratio than Lipocine, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Lipocine$1.98M9.41-$9.63M-$1.88N/A
Mustang BioN/AN/A-$1.92M-$0.48N/A

Summary

Lipocine and Mustang Bio tied by winning 7 of the 14 factors compared between the two stocks.

How does Mustang Bio compare to Pasithea Therapeutics?

Pasithea Therapeutics (NASDAQ:KTTA) and Mustang Bio (NASDAQ:MBIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

23.9% of Pasithea Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Mustang Bio shares are held by institutional investors. 2.0% of Pasithea Therapeutics shares are held by company insiders. Comparatively, 4.0% of Mustang Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Pasithea Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 328.69%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Pasithea Therapeutics is more favorable than Mustang Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pasithea Therapeutics
2 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.67
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Pasithea Therapeutics had 7 more articles in the media than Mustang Bio. MarketBeat recorded 7 mentions for Pasithea Therapeutics and 0 mentions for Mustang Bio. Pasithea Therapeutics' average media sentiment score of 0.75 beat Mustang Bio's score of 0.00 indicating that Pasithea Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Pasithea Therapeutics Positive
Mustang Bio Neutral

Pasithea Therapeutics has a beta of 0.22, indicating that its stock price is 78% less volatile than the broader market. Comparatively, Mustang Bio has a beta of 2.11, indicating that its stock price is 111% more volatile than the broader market.

Mustang Bio's return on equity of -35.38% beat Pasithea Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Pasithea TherapeuticsN/A -57.44% -53.61%
Mustang Bio N/A -35.38%-16.36%

Mustang Bio is trading at a lower price-to-earnings ratio than Pasithea Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pasithea TherapeuticsN/AN/A-$20.43M-$2.08N/A
Mustang BioN/AN/A-$1.92M-$0.48N/A

Summary

Pasithea Therapeutics beats Mustang Bio on 7 of the 13 factors compared between the two stocks.

How does Mustang Bio compare to Quince Therapeutics?

Mustang Bio (NASDAQ:MBIO) and Quince Therapeutics (NASDAQ:QNCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, earnings, dividends, risk, analyst recommendations and institutional ownership.

10.0% of Mustang Bio shares are held by institutional investors. Comparatively, 30.8% of Quince Therapeutics shares are held by institutional investors. 4.0% of Mustang Bio shares are held by insiders. Comparatively, 20.3% of Quince Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Quince Therapeutics has a consensus target price of $65.00, indicating a potential upside of 5,809.09%. Given Quince Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Quince Therapeutics is more favorable than Mustang Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mustang Bio
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Quince Therapeutics
2 Sell rating(s)
5 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.71

In the previous week, Quince Therapeutics had 1 more articles in the media than Mustang Bio. MarketBeat recorded 1 mentions for Quince Therapeutics and 0 mentions for Mustang Bio. Quince Therapeutics' average media sentiment score of 0.08 beat Mustang Bio's score of 0.00 indicating that Quince Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Mustang Bio Neutral
Quince Therapeutics Neutral

Mustang Bio has a beta of 2.11, suggesting that its stock price is 111% more volatile than the broader market. Comparatively, Quince Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Mustang Bio's return on equity of -35.38% beat Quince Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Mustang BioN/A -35.38% -16.36%
Quince Therapeutics N/A -372.88%-67.99%

Mustang Bio is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mustang BioN/AN/A-$1.92M-$0.48N/A
Quince TherapeuticsN/AN/A-$83.98M-$10.62N/A

Summary

Quince Therapeutics beats Mustang Bio on 7 of the 12 factors compared between the two stocks.

Get Mustang Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for MBIO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MBIO vs. The Competition

Export
MetricMustang BioMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.79M$3.37B$6.46B$12.34B
Dividend YieldN/A2.26%2.76%5.28%
P/E Ratio-1.3218.7421.0025.66
Price / SalesN/A323.98558.1986.31
Price / CashN/A125.1743.4956.67
Price / Book0.567.0910.407.14
Net Income-$1.92M$24.45M$3.57B$335.98M
7 Day Performance-1.53%6.38%6.40%4.11%
1 Month Performance-16.17%2.43%3.55%2.52%
1 Year Performance-49.43%62.98%34.13%35.04%

Mustang Bio Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MBIO
Mustang Bio
0.5904 of 5 stars		$0.63
flat		N/A-49.4%$4.79MN/AN/A100
ANEB
Anebulo Pharmaceuticals
0.0325 of 5 stars		$0.46
-9.7%		N/A-58.9%$18.76MN/AN/A4
XCUR
Exicure
0.5405 of 5 stars		$2.89
-5.6%		N/A-72.0%$18.41M$500KN/A50
LPCN
Lipocine
2.9104 of 5 stars		$2.20
-0.5%		$15.00
+581.8%		-36.9%$18.14M$2.00MN/A10
KTTA
Pasithea Therapeutics
2.8091 of 5 stars		$0.70
-8.8%		$3.00
+327.0%		-23.5%$17.52MN/AN/A3

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:MBIO) was last updated on 5/26/2026 by MarketBeat.com Staff.
From Our Partners
Hey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...
After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...
Banyan Hill Publishing | Sponsoredtc pixel
The SpaceX supplier that shipped 5 billion chips to Starlink
When Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...
Weiss Ratings | Sponsoredtc pixel
Three companies about to leapfrog Nvidia [And transform the entire industry]
Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...
Eagle Publishing | Sponsoredtc pixel
The S-1 just dropped. 22 days left.
The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...
Behind the Markets | Sponsoredtc pixel
My crisis of conscience
Emmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...
Profits Run | Sponsoredtc pixel
Opportunity Forming in a U.S. Supply-Chain Weak Spot?
America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...
i2i Marketing Group, LLC | Sponsoredtc pixel
Skip the Line Opportunity: The SpaceX IPO
Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...
Brownstone Research | Sponsoredtc pixel